

Synthesis of 1,8-Diazaanthracenes as Building Blocks for Internally Functionalized Aromatic Oligoamide Foldamers

Michael L. Singleton,^{†,‡} Nicola Castellucci,^{†,‡,§} Stéphane Massip,^{||,⊥,#} Brice Kauffmann,^{||,⊥,#} Yann Ferrand,^{†,‡} and Ivan Huc^{*,†,‡}

[†]University of Bordeaux, CBMN (UMR 5248), Institut Européen de Chimie Biologie, 2 rue Robert Escarpit, 33600 Pessac, France

[‡]CNRS, CBMN (UMR 5248), 2 rue Robert Escarpit, 33600 Pessac, France


[§]Dipartimento di Chimica "G. Ciamician" Alma Mater Studiorum Università di Bologna via Selmi 2, 40126 Bologna, Italy

^{||}University of Bordeaux, Institut Européen de Chimie Biologie (UMS 3033/US 001), 2 rue Robert Escarpit, 33600 Pessac, France

[⊥]CNRS, Institut Européen de Chimie Biologie (UMS 3033), 2 rue Robert Escarpit, 33600 Pessac, France

[#]INSERM, Institut Européen de Chimie Biologie (US 001), 2 rue Robert Escarpit, 33600 Pessac, France

Supporting Information



ABSTRACT: The synthesis of a variety of 9-functionalized 1,8-diazaanthracene diesters and amino acids is described. Derivatization at the 9-position relies on facile reactions performed on the 9-chloro and 9-bromomethyl precursors. This has allowed the incorporation of nucleophilic or sensitive functional groups that otherwise cannot be incorporated under standard methods for synthesizing these compounds. Additionally, the synthesis of the protected amino acids via a high-yielding monosaponification and subsequent Curtius rearrangement has been accomplished on a multigram scale. These units, together with the functionalized derivatives, should prove to be useful monomers in the synthesis of aromatic oligoamide foldamers.

INTRODUCTION

The past decade has seen a significant advancement in the synthesis of molecules designed to mimic both structural and functional aspects of biopolymers.^{1,2} Chemists can now readily synthesize oligomeric or even polymeric systems that, through the same principles that direct folding in biological molecules, adopt complex secondary structural features including helices, linear strands, and, more rarely, sheets.^{3–8} These artificial folded molecular architectures, termed foldamers,⁹ are typically comprised of small distinct units that, when connected together, self-organize into specifically shaped macromolecules, the properties of which are dependent on the composition of the monomers used. In this respect, the development of new foldamers can be said to be monomer driven. Thus, the synthesis of novel monomer units is an important endeavor for expanding the diversity of this class of molecules.

While the majority of synthetic foldamers make use of aliphatic units derived from α -amino acids or the homologous β - and γ -amino acids,^{10–12} the myriad of chemical building

blocks afforded to chemists has given rise to folded systems more distinctly removed from their natural counterparts. These include, but are not limited to, oligomers comprised of *m*-phenylene ethynyls,^{13,14} pyridine-pyridazines,^{15,16} ureas,^{17,18} and aromatic amides.^{19,20} This last group, aromatic oligoamide foldamers, has shown particular promise in the development of complex architectures as a result of their high predictability, stability, and tunability.

The connection of aromatic rings via an amide linkage gives a planar or close to planar system as a result of conjugation. Thus, with a functionalized aromatic ring, one of two conformations can be expected, with the preference for *syn* versus *anti* dictated by the local attractive and repulsive electrostatic interactions between the amide and any endo- or exocyclic heteroatoms on the ring (Figure 1a).^{19,20} Extension of these principles to subsequent monomers consequently results

Received: December 23, 2013

Published: February 7, 2014




Figure 1. (a) Conformational exchange between *syn* and *anti* forms of an aromatic amide. (b, c) Examples of aromatic building blocks for aromatic oligoamides, including 1,8-diazaanthracenes (c) that have been used for foldamer synthesis. (d) Potential ways for using 1,8-diazaanthracenes for arranging convergent functional groups in a helical foldamer scaffolds.

in an overall structure that is defined by the collection of local conformational preferences. In the case of helical structures, where these preferences bring the additional monomers around in a full turn, steric interactions result in the strand being twisted out of planarity and the secondary structure that begins to form being further stabilized by aromatic π - π stacking interactions.


Monomers for these designs (Figure 1b,c), as long as they fulfill the structural requirements described above, can be readily modified to tune many of the properties of the foldamers, including solubility, curvature, and aggregative tendencies. Specifically, by tuning the width of the monomers in a sequence and the angle between their amino and carboxy groups, large cavities capable of encapsulating guest molecules can be developed. Several such systems based on aromatic oligoamides have now been reported.^{21–26} However, current limitations on these systems involve both limited cavity sizes and limited functional group diversity on the interior surfaces.

Pyrido[3,2-*g*]quinolines, hereafter referred to as 1,8-diazaanthracenes in this paper (Figure 1c), represent an attractive candidate for expanding both the size and the interior complexity of such helical receptors. These units offer a long distance (~ 9 Å) and wide angle ($\sim 120^\circ$) between connection sites at positions 2 and 7, which can allow interior cavities of exceptionally large size to be synthesized. Additionally, because only the outer two aromatic rings are used for structural stability by means of their endocyclic nitrogen atom, the central ring, i.e. position 9, can be modified in order to potentially provide enhanced interactions between the host and guest molecules or even provide catalytic sites through the use of functional groups that converge toward the interior of a helical cavity (Figure 1d). As a class of molecules, 1,8-diazaanthracenes

have been studied for both their photophysical and pharmaceutical applications.^{27–30} Despite this, the variety of such compounds is not extensive, and while units of this type have been used in the development of helical aromatic oligoamides,^{24–26,31–34} their diversity has been limited to the two units shown in Figure 1c.

The typical synthetic route to make these molecules likely contributes to this limited diversity (Scheme 1). The synthesis

Scheme 1. Typical Synthesis of 1,8-Diazaanthracenes^a



^aReaction conditions: (a) dimethyl acetylenedicarboxylate, MeOH; (b) Ph₂O, Δ; (c) diisopropyl azodicarboxylate, PPh₃, ROH, THF.

is accomplished via an initial Michael addition of 2 equiv of dimethyl acetylenedicarboxylate to the appropriate 1-function-ized 2,6-diaminobenzene.²⁷ Thermal cyclization in refluxing diphenyl ether at 260 °C and then alkylation of the resulting 4,5-dihydroxy-1,8-diazaanthracenes under Mitsunobu conditions give the final monomers.^{23,26,33} Through this protocol, variation of the 9-position substituent is limited to the range of functional groups that can be incorporated into the starting diaminobenzene moiety and that are capable of withstanding the harsh conditions of the cyclization step: i.e., either high temperature²⁷ or strongly acidic conditions.³⁵ In addition, this route requires a substituent on the diaminobenzene precursor and does not allow one to directly reach the 9-H 1,8-diazaanthracene. Without this substituent, a 1,7-phenanthroline is obtained instead of a 1,8-diazaanthracene.^{27,36}


For modification of the 9-position, it would be ideal to have monomers that could be readily modified after their initial synthesis. The current work provides methods for easily introducing a number of aromatic and alkyl functional groups at the 9-position of the diazaanthracene monomers. Furthermore, because functionalization takes place after the cyclization step, previously unobtainable monomers, such as the 9-hydro derivative, are now accessible.^{27,36}

Additionally, the synthetic route affords symmetrical units having ester functional groups both in the 2- and 7-positions. This has until now hampered the production of multimeric segments of 1,8-diazaanthracene units, their development being limited to the use of less stable connections such as anhydrides.³³ In order to increase the applicability of these units in the synthesis of aromatic oligoamides, two methods for the desymmetrization of the monomers and formation of the amino acids are reported here. Through these synthetic routes, a novel class of large aromatic amino acids with a variety of side chains has been obtained.

RESULTS AND DISCUSSION

Derivatization of the 9-Position of the Diazaanthracenes.

As shown in Scheme 2, the starting materials for diversification of the diazaanthracene series are the 9-methyl³⁴

Scheme 2. Derivatization of Diazaanthracene Units^a

^aReaction conditions: (a) NBS, BPO, C₆H₆, 60 °C, 89%; (b) Ag₂CO₃, dioxane/H₂O, Δ, 80%; (c) AgOAc, dioxane, 91%; (d) AgONO₂, dioxane, 81%; (e) (1) AgOAc, dioxane, (2) MeOH, H₂SO₄ cat. 80%; (f) AgONO₂, dioxane, then Et₃N, dioxane, Δ, 41%; (g) NaN₃, 15-crown-5, dioxane, 71%; (h) (1) KNBoc₂, DMF, 50 °C, (2) Mg(ClO₄)₂, MeCN, Δ, 80%; (i) methylimidazole, Δ, 83%; (j) NaN₃, PPh₃, DMF, Δ, 61%; (k) NaN₃, PPh₃, DMF, Δ, then Boc₂O, DMAP, dioxane, Δ, 80%; (l) HSBn, Cs₂CO₃, toluene 86%; (m) Pd/C, H₂, K₂CO₃, DMF, 79%; (n) C/O₂, toluene, 100 °C, 83%.

(compound **1**) and 9-chloro (compound **2-Cl**) derivatives, both readily obtained from reaction of the corresponding pyrido-quinolinone with isobutyl alcohol under Mitsunobu conditions. **1** can be brominated in the benzylic position using *N*-bromosuccinimide and benzoyl peroxide to give **1-Br** in good yield (89%). Subsequent substitution of the bromide by reaction of Ag₂CO₃, AgOAc, or AgONO₂ gave the derivatives **1-OH**, **1-OAc**, and **1-ONO₂**, respectively. Interestingly, while both the acetate and nitrate ester groups were initially planned as methods for getting to the alcohol, the nitrate ester proved resistant to hydrolysis by water and attempted transesterification of the acetate derivative by methanol in the presence of catalytic sulfuric acid instead resulted in the formation of the methyl ether derivative **1-OMe**. The nitrate ester, however, appears to be a reasonable precursor for synthesis of the aldehyde derivative **1=O**, by reaction with multiple equivalents of Et₃N in refluxing dimethoxyethane.

Nitrogen-containing side chains are similarly incorporated. The reaction of 5 equiv of sodium azide with **1-Br** in the presence of 15-crown-5 proceeds at room temperature to give

1-N₃ in good yield. However, attempted reduction of the azide to the amine did not give good conversion either by standard reduction with Pd/C and H₂ or by a Staudinger reduction using PPh₃. Instead, a Gabriel-type synthesis of the amine was used by initially substituting **1-Br** with di-*tert*-butylimidocarbonate to give the bis(*tert*-butoxycarbonyl)-protected benzylic amine.³⁷ Selective mono-Boc deprotection using Mg(ClO₄)₂ in refluxing MeCN gave the derivative **1-NHBoc** in 80% yield across the two steps.

Cationic nitrogen centers could also be generated quite readily. The reaction of *N*-methylimidazole with **1-Br** gave the imidazolium salt **1-imid** in 83% yield after precipitation in diethyl ether. In addition to the positive charge that it can provide, this derivative could also provide carbene-based reactivity inside of a foldamer capsule.

2-Cl could similarly be derivatized through nucleophilic displacement of the chloride. Sulfur-based nucleophiles readily add to the diazaanthracene. Even at room temperature, the reaction of benzyl mercaptan with **2-Cl** in the presence of Cs₂CO₃ proceeds to give **2-SBn** as a bright red solid in 86% yield.

In order to obtain the 9-amino derivative **2-NH₂**, it was envisaged that reaction of **2-Cl** with NaN₃ in DMF would give an intermediate azide bearing diazaanthracene that could be reduced to give the amine. However, at the temperatures required for substitution to occur, the resulting azide decomposed, presumably to the nitrene, and gave a mixture of species, including the amine, in low yield (<30%) as well as an unstable species assigned to the 9-azido complex on the basis of a strong IR signal at 2116 cm⁻¹ (KBr pellet), and several unidentified species attributed to decomposition products resulting from side reactions with the nitrene intermediate. By combining the displacement and reductive steps through the addition of PPh₃ to the reaction mixture, as described by Kandakar et al.,³⁸ the yield could be greatly increased (61%) and the amine obtained as a bright red crystalline solid after workup.

Protection of **2-NH₂** by reaction with Boc₂O proceeds only at high temperatures and with the addition of DMAP. Under these conditions, the reaction cannot be stopped at the mono-Boc complex. Rather, even when the reaction is stopped before completion, only starting material and the di-Boc complex **2-NBoc₂** are observed.

Most importantly for complex **2-Cl**, it provides a method for the synthesis of the 9-hydro compound **2**, an ideal unit for designing large foldamer capsules because of its lack of space-filling functional groups. Hydrodehalogenation of **2-Cl** occurs readily in DMF with K₂CO₃ as a base. The use of a weaker base such as Et₃N or less polar solvent does not give the desired hydrodehalogenation; rather, the major product is a 1,2,3,4-tetrahydropyrido[3,2-*g*]quinoline species, **2-Cl^{red}** (Figure 2c), resulting from reduction of one of the pyridine rings. Even under the ideal conditions the initial product from the hydrodehalogenation, the 9-hydro compound **2**, is further reduced to the 9,10-dihydro compound **2-H₂**. Despite our best efforts to stop the reaction before the second reduction occurs, a mixture of both products was always obtained. Compound **2-H₂** can, however, be reoxidized back to the fully aromatic **2**.

While several conditions for the reoxidation were tested, including MnO₂, DDQ, and Pd/C under N₂, the best results were obtained from activated C and O₂³⁹ in refluxing toluene. The reaction progress was monitored by ¹H NMR through loss of the triplet signals at 4.53 and 4.07 ppm and the appearance




Figure 2. Top (left) and side (right) views of ball and stick representations of the X-ray crystal structures of (a) **2**, (b) **2-H₂**, and (c) the tetrahydropyrido[3,2-*g*]quinoline byproduct **2-Cl^{red}** from failed hydrodehalogenation attempts. Protons and included solvent molecules have been removed, and in the top view, isobutoxy side chains have been shortened for clarity.


of two singlets at 9.29 and 9.20 ppm consistent with the oxidation of the central ring. The combined yield for both the reduction and reoxidation steps is close to 66%, and compound **2** can be obtained in multigram quantities. The lack of a functional group in the 9-position now allows other derivatives to be synthesized through electrophilic aromatic reactions. As one example, **2** was converted into the 9-bromo compound **2-Br** through reaction with NBS at elevated temperature.

Compounds **2**, **2-H₂**, and the byproduct with the reduced pyridine ring were all characterized by X-ray crystallography (Figure 2). While the byproduct (Figure 2c) shows significant differences from both **2** and **2-H₂**, the latter compounds are very similar in structure with the central ring of **2-H₂**, showing only minor distortion into a chair conformation. The change in C–C bond lengths between the 9- or 10-position carbons and the adjacent pyridine rings, 1.49 Å in **2-H₂** to 1.40 Å in **2**, is nevertheless consistent with the different degrees of saturation in the central ring.

Desymmetrization and Amino Acid Synthesis. As stated earlier, for the facile synthesis of diazaanthracene oligoamide segments, it would be ideal to develop amino acid derivatives. This involves two important steps: the first is the desymmetrization by monosaponification of the equivalent diesters, and the second is the conversion of the resulting acid into the protected amine functionality. As shown in Scheme 3, the synthetic approach is different depending on the starting compound.

For both **1** and **2**, high yields in the monosaponification step rely on the limited solubility of the monocarboxylate salt. With **1**, it was found that a 75/25 THF/MeOH solvent mixture and NaOH as the base gave **3-Me** in the best yields, while for **2**, initial solvation in hot methanol followed by the addition of KOH afforded **3** in 90% yield after a short reaction time at 60 °C followed by reaction overnight at 35 °C. For both compounds the carboxylate salt precipitates out and can be

Scheme 3. Synthesis of Protected Amino Acids **4 and **4-Me**^a**



^aReaction conditions: (a) NaOH, THF/MeOH, 89%; (b) (1) oxalyl chloride, CHCl₃, (2) TMSN₃, CHCl₃, (3) *t*BuOH, Δ, 77%; (c) KOH, MeOH, 60–30 °C, 90%; (d) dppe, toluene, room temperature, then toluene, *t*BuOH, Δ, 62%.

isolated in a pure form by filtration. For **3-Me**, the compound was left as the sodium salt and used this way for subsequent steps, while for **3**, the product was washed with a citric acid solution to obtain the acid. Compound **3-Me** was converted into the Boc-protected amino acid through initial reaction with oxalyl chloride followed by acyl azide formation with trimethylsilyl azide. The Curtius rearrangement was performed in refluxing *tert*-butyl alcohol to give the Boc-protected amine **4-Me**. As a side product of this reaction, a dimeric species, **4-dimer**, was observed where the nitrene that formed during the rearrangement underwent an intermolecular C–H insertion at the position ortho to the methyl ester in a second molecule of diazaanthracene (Figure 3). While the formation of this side product could be limited by further dilution of the reaction, it was never fully eliminated under the conditions used.




Figure 3. Ball and stick representation of the X-ray crystal structure of the dimeric byproduct **4-dimer**. Protons and included solvent molecules have been removed and isobutoxy side chains shortened for clarity.

Use of a similar scheme for **3** resulted in low yields as a result of instability during the acid chloride formation. Unlike **3-Me**, which stays yellow after reaction with the oxalyl chloride, a solution of **3** turns black and little or no product is obtained. Similar results were obtained with thionyl chloride and 1-chloro-*N,N*,2-trimethylpropenylamine. As an alternative, diphenylphosphoryl azide was used, but it required first an initial reaction in toluene overnight at room temperature, followed by further dilution with toluene and *t*BuOH before heating to reflux for several hours. This dilution step is again required to limit the formation of byproducts that occur during the Curtius rearrangement.

CONCLUSION

All compounds described above represent derivatives that are difficult to obtain in good yield through the standard synthetic routes described for the precursors **1** and **2-Cl**. Additionally, the methods for desymmetrization and conversion to the protected amino acids have provided large, rigid aromatic units that should serve as important building blocks in the development of supramolecular architectures. The synthetic routes described for these compounds offer a complementary method for incorporating functional groups into aromatic oligoamide foldamers for the purposes of molecular recognition or reactivity. Studies looking at incorporating these units into longer sequences are under way and will be reported in due course.

EXPERIMENTAL SECTION

General Procedures. Unless otherwise stated, all solvents and reagents were used without further purification. When required, dry solvents and bases were obtained directly prior to use by either distilling from CaH₂ (CHCl₃, triethylamine, and diisopropylethylamine) or drying over alumina (THF, toluene, and DCM). All solvent mixtures for chromatography are reported as v/v. Compound **1** and dimethyl 10-chloro-4,6-dioxo-1,4,6,9-tetrahydropyrido[3,2-*g*]-quinoline-2,8-dicarboxylate were synthesized as previously reported.^{27,34} ¹H and ¹³C NMR chemical shifts are reported in ppm and are calibrated against residual ¹H and ¹³C solvent signals of CDCl₃ (δ 7.26, 77.2) and DMSO-*d*₆ (δ 2.50, 39.4). The following notation is used for the ¹H NMR spectral splitting patterns: singlet (s), broad singlet (bs), doublet (d), triplet (t), multiplet (m). High-resolution electrospray ionization orbitrap (ESI-orbitrap) mass spectra were measured in the positive ion mode.

Synthesis. *Dimethyl 1,8-Diaza-4,5-diisobutoxy-9-(bromomethyl)-2,7-anthracenedicarboxylate (1-Br)*. In a 100 mL round-bottomed flask, **1** (5.00 g, 11.0 mmol), freshly recrystallized NBS (2.15 g, 12.1 mmol, 1.1 equiv), and benzoyl peroxide (1.33 g, 5.5 mmol, 0.5 equiv) were slurried in benzene (30 mL). The mixture was then heated to 65 °C and stirred overnight. Solvent was removed by rotary evaporation, and the yellow residue was recrystallized from DCM/MeOH to yield **1-Br** as yellow crystals (5.2 g, 89%). ¹H NMR (CDCl₃, 300 MHz): δ 9.27 (s, 1H), 7.51 (s, 2H), 6.16 (s, 2H), 4.14 (d, ³J_{HH} = 6.4 Hz, 4H), 4.10 (s, 6H), 2.36 (m, 2H), 1.19 (d, ³J_{HH} = 6.8 Hz, 12H). ¹³C NMR (CDCl₃, 75 MHz): δ 166.4, 163.5, 151.0, 145.1, 135.9, 121.9, 117.2, 99.4, 75.4, 53.4, 28.4, 25.3, 19.3. Mp: 253–255 °C. HRMS (ESI): *m/z* calcd for C₂₅H₃₀BrN₂O₆ [M + H]⁺ 533.1287, found 533.1287. X-ray structure: see the Supporting Information.

Dimethyl 1,8-Diaza-4,5-diisobutoxy-9-[(tert-butoxycarbonyl)amino]methyl-2,7-anthracenedicarboxylate (1-NHBoc). In a dry 50 mL round-bottomed flask **1-Br** (5.00 g, 9.4 mmol) and potassium di-*tert*-butyliminodicarbonate^{37,40} (2.89 g, 11.3 mmol, 1.2 equiv) were slurried in 20 mL of anhydrous DMF under an inert gas atmosphere. The flask was then heated to 50 °C for 12 h. Solvent was removed on the vacuum line, and then the crude residue was dissolved in 10 mL of MeCN. The mixture was heated to reflux, and Mg(ClO₄)₂ (0.21 g, 0.9

mmol, 0.1 equiv) was added. The reaction was carefully monitored by TLC and stopped when the intermediate product was no longer visible (~30 min). The reaction mixture was diluted with 100 mL of EtOAc and washed with first water and then brine solution. The organic layer was dried over MgSO₄ and filtered, and then the solvent was removed by rotary evaporation. The crude yellow solid was recrystallized with DCM/MeOH to give **1-NHBoc** as a yellow solid (4.31 g, 81%). ¹H NMR (CDCl₃, 300 MHz): δ 9.23 (s, 1H), 7.52 (s, 2H), 6.4 (bs, 1H), 5.79 (d, 2H, ³J_{HH} = 5.6 Hz), 4.15 (d, ³J_{HH} = 6.4 Hz, 4H), 4.09 (s, 6H), 2.37 (m, 2H), 1.42 (s, 9H), 1.20 (d, ³J_{HH} = 6.6 Hz, 12H). ¹³C NMR (CDCl₃, 75 MHz): δ 166.4, 163.7, 156.4, 150.4, 145.6, 145.6, 121.8, 116.0, 98.9, 78.8, 75.4, 53.3, 38.2, 28.7, 28.4, 19.3. Mp: 215–218 °C. HRMS (ESI): *m/z* calcd for C₃₀H₄₀N₃O₈ [M + H]⁺ 570.2815, found 570.2817.

Dimethyl 1,8-Diaza-4,5-diisobutoxy-9-[azidomethyl]-2,7-anthracenedicarboxylate (1-N₃). In a dry 50 mL round-bottomed flask **1-Br** (1.00 g, 1.9 mmol) and sodium azide (0.52 g, 9.4 mmol, 5.0 equiv) were slurried in 15 mL of dioxane. 15-crown-5 (0.5 mL) was added, and the reaction mixture was stirred at room temperature for 72 h. Solvent was removed, and the crude yellow solid was redissolved in 100 mL of dichloromethane. The solution was then filtered through Celite to remove the residual salts. Solvent was removed on a rotary evaporator, and the crude product was recrystallized from DCM/MeOH to give **1-N₃** as a yellow solid (0.90 g, 97%). ¹H NMR (CDCl₃, 300 MHz): δ 9.29 (s, 1H), 7.52 (s, 2H), 5.87 (s, 2H), 4.15 (d, ³J_{HH} = 6.2 Hz, 4H), 4.08 (s, 6H), 2.37 (m, 2H), 1.20 (d, ³J_{HH} = 6.6 Hz, 12H). ¹³C NMR (CDCl₃, 75 MHz): δ 166.4, 163.6, 151.2, 146.1, 134.3, 121.8, 117.3, 99.3, 75.5, 53.3, 45.0, 28.5, 19.3. Mp: 231–235 °C. HRMS (ESI): *m/z* calcd for C₂₅H₃₀N₃O₆ [M + H]⁺ 496.2191, found 496.2194. X-ray structure: see the Supporting Information.

Dimethyl 1,8-Diaza-4,5-diisobutoxy-9-[(acetyloxy)methyl]-2,7-anthracenedicarboxylate (1-OAc). In a dry 50 mL round-bottomed flask **1-Br** (1.00 g, 1.9 mmol) and silver acetate (0.47 g, 2.8 mmol, 1.5 equiv) were slurried in 30 mL of dioxane. The reaction mixture was heated to 60 °C and stirred overnight. The solution was poured into dichloromethane (100 mL) and then filtered through Celite to remove the residual silver salts. Solvent was removed on a rotary evaporator, and the crude product was recrystallized from DCM/MeOH to give **1-OAc** as a yellow solid (0.80 g, 91%). ¹H NMR (CDCl₃, 300 MHz): δ 9.36 (s, 1H), 7.54 (s, 2H), 6.68 (s, 2H), 4.18 (d, ³J_{HH} = 6.4 Hz, 4H), 4.11 (s, 6H), 2.40 (m, 2H), 2.11 (s, 3H), 1.23 (d, ³J_{HH} = 6.7 Hz, 12H). ¹³C NMR (CDCl₃, 75 MHz): δ 171.2, 166.5, 163.5, 151.1, 146.3, 133.5, 121.6, 117.7, 99.0, 75.4, 58.0, 53.2, 28.4, 21.3, 19.3. Mp: 211–213 °C. HRMS (ESI): *m/z* calcd for C₂₇H₃₃N₂O₈ [M + H]⁺ 513.2237, found 513.2235. X-ray structure: see the Supporting Information.

Dimethyl 1,8-Diaza-4,5-diisobutoxy-9-(hydroxymethyl)-2,7-anthracenedicarboxylate (1-OH). In a dry 25 mL round-bottomed flask **1-Br** (0.60 g, 1.1 mmol) and silver carbonate (0.62 g, 2.3 mmol, 2.0 equiv) were slurried in 10 mL of a 10% H₂O/dioxane solution under an inert gas atmosphere. The reaction mixture was then stirred for 12 h at 90 °C. DCM (30 mL) was added, and the solution was passed through Celite to remove the precipitated silver salts. Solvent was removed on a rotary evaporator, and the crude yellow solid was recrystallized with DCM/MeOH to give **1-OH** as a yellow solid (0.43 g, 80%). ¹H NMR (CDCl₃, 300 MHz): δ 9.22 (s, 1H), 7.50 (s, 2H), 6.36 (t, ³J_{HH} = 6.6 Hz, 1H), 6.15 (d, ³J_{HH} = 6.4 Hz, 2H), 4.14 (d, ³J_{HH} = 6.4 Hz, 4H), 4.08 (s, 6H), 2.37 (m, 2H), 1.20 (d, ³J_{HH} = 6.8 Hz, 12H). ¹³C NMR (CDCl₃, 75 MHz): δ 166.1, 163.8, 150.0, 145.3, 137.9, 121.6, 115.9, 98.9, 75.4, 59.9, 53.4, 28.4, 19.3. Mp: 235–237 °C. HRMS (ESI): *m/z* calcd for C₂₅H₃₁N₂O₇ [M + H]⁺ 471.2131, found 471.2126.

Dimethyl 1,8-Diaza-4,5-diisobutoxy-9-(nitrooxymethyl)-2,7-anthracenedicarboxylate (1-ONO₂). In a dry 50 mL round-bottomed flask **1-Br** (0.50 g, 0.9 mmol) and silver nitrate (0.24 g, 1.4 mmol, 1.5 equiv) were slurried in 20 mL of dioxane under an inert gas atmosphere. The reaction mixture was then stirred for 12 h at room temperature. DCM (30 mL) was added, and the solution was passed through Celite to remove the precipitated silver salts. Solvent was removed on a rotary evaporator, and the crude yellow solid was recrystallized with DCM/MeOH to give **1-ONO₂** as a yellow solid

(0.39 g, 81%). ^1H NMR (CDCl_3 , 300 MHz): δ 9.36 (s, 1H), 7.51 (s, 2H), 7.07 (s, 2H), 4.15 (d, $^3J_{\text{HH}} = 6.4$, 4H), 4.08 (s, 6H), 2.37 (m, 2H), 1.20 (d, $^3J_{\text{HH}} = 6.8$ Hz, 2H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 166.1, 163.5, 151.6, 146.5, 128.8, 121.5, 119.0, 99.3, 75.5, 66.6, 53.3, 28.4, 19.3. Mp: 224–227 °C. HRMS (ESI): m/z calcd for $\text{C}_{25}\text{H}_{30}\text{N}_2\text{O}_9$ [$\text{M} + \text{H}$] $^+$ 516.1982, found 516.1978. X-ray structure: see the Supporting Information.

Dimethyl 1,8-Diaza-4,5-diisobutoxy-9-[(methoxy)methyl]-2,7-anthracenedicarboxylate (1-OMe). In a dry 25 mL round-bottomed flask **1-OAc** (0.10 g, 0.2 mmol) was slurried in 20 mL of MeOH. Concentrated sulfuric acid (0.01 mL, 0.2 mmol, 1.0 equiv) was added, and the reaction mixture was stirred at reflux for 3 h. The mixture was then neutralized with a saturated solution of NaHCO_3 , and the product was extracted with DCM. Solvent was removed on a rotary evaporator, and the crude yellow solid was recrystallized with DCM/MeOH to give **1-OMe** as a yellow solid (0.08 g, 80%). ^1H NMR (CDCl_3 , 300 MHz): δ 9.29 (s, 1H), 7.50 (s, 2H), 5.97 (s, 2H), 4.14 (d, $^3J_{\text{HH}} = 6.4$, 4H), 4.08 (s, 6H), 3.64 (s, 3H), 2.36 (m, 2H), 1.20 (d, $^3J_{\text{HH}} = 6.6$ Hz, 12H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 166.5, 163.4, 151.0, 146.5, 135.8, 121.7, 117.1, 99.0, 75.3, 64.6, 59.4, 53.2, 28.4, 19.3. Mp: 211–214 °C. HRMS (ESI): m/z calcd for $\text{C}_{26}\text{H}_{33}\text{N}_2\text{O}_7$ [$\text{M} + \text{H}$] $^+$ 485.2282, found 485.2285.

Dimethyl 1,8-Diaza-4,5-diisobutoxy-9-(formyl)-2,7-anthracenedicarboxylate (1=O). In a dry 50 mL round-bottomed flask **1-ONO₂** (0.40 g, 0.8 mmol) was slurried in 30 mL of dry dioxane. Triethylamine (0.97 mL, 8.0 mmol, 10.0 equiv) was added, and the reaction mixture was heated to 85 °C for 16 h. The reaction mixture was poured into ice–water, and the product was extracted into DCM. Solvent was removed on a rotary evaporator, and the crude yellow solid was purified by column chromatography with cyclohexane/acetone to give **1=O** as a light yellow solid (0.15 g, 41%). ^1H NMR (CDCl_3 , 300 MHz): δ 11.86 (s, 1H), 9.51 (s, 1H), 7.58 (s, 2H), 4.17 (d, $^3J_{\text{HH}} = 6.4$, 4H), 4.09 (s, 6H), 2.38 (m, 2H), 1.21 (d, $^3J_{\text{HH}} = 6.8$ Hz, 12H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 194.5, 166.1, 163.6, 152.9, 146.8, 129.4, 122.5, 121.7, 99.70, 75.6, 53.61, 28.4, 19.3. Mp: 252–255 °C. HRMS (ESI): m/z calcd for $\text{C}_{25}\text{H}_{29}\text{N}_2\text{O}_7$ [$\text{M} + \text{H}$] $^+$ 469.1975, found 469.1970.

Dimethyl 1,8-Diaza-4,5-diisobutoxy-9-[N-(N'-methylimidazolium)methyl]-2,7-anthracenedicarboxylate (1-imid). In a dry 50 mL round-bottomed flask **1-Br** (0.50 g, 0.9 mmol) was slurried in 20 mL of methylimidazole. The reaction mixture was then stirred overnight at 60 °C. The solution was cooled to room temperature, and diethyl ether (100 mL) was added. The powdery yellow product was collected by filtration and dried on the filter to give **1-imid** as a yellow solid (0.48 g, 83%). ^1H NMR (CDCl_3 , 300 MHz): δ 9.55 (s, 1H), 9.34 (s, 1H), 7.88 (s, 1H), 7.70 (s, 1H), 7.53 (s, 2H), 6.71 (s, 2H), 4.18 (s, 6H), 4.17 (d, $^3J_{\text{HH}} = 6.8$ Hz, 4H), 4.15 (s, 3H), 2.38 (m, 2H), 1.19 (d, $^3J_{\text{HH}} = 6.6$ Hz, 12H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 165.7, 164.1, 151.8, 145.4, 137.4, 129.7, 124.2, 123.0, 121.7, 119.4, 99.6, 75.7, 53.8, 43.9, 37.3, 28.3, 19.2. Mp: 192–195 °C. HRMS (ESI): m/z calcd for $\text{C}_{29}\text{H}_{35}\text{N}_4\text{O}_6$ [$\text{M} + \text{H}$] $^+$ 535.2551, found 535.2552.

Dimethyl 1,8-Diaza-4,5-diisobutoxy-9-chloro-2,7-anthracenedicarboxylate (2-Cl). In a dry 1 L round-bottomed flask, a mixture of dimethyl 10-chloro-4,6-dioxo-1,4,6,9-tetrahydropyrido[3,2-g]-quinoline-2,8-dicarboxylate (26.0 g, 71.8 mmol), freshly distilled 2-methylpropanol (15.2 mL, 158.0 mmol, 2.2 equiv), and triphenylphosphine (41.4 g, 158.0 mmol, 2.2 equiv) was suspended in 500 mL of anhydrous THF (freshly distilled). The flask was then hermetically closed and remained under protecting gas during the reaction time. (The reagents are not soluble in THF before the addition of diisopropyl azodicarboxylate). The reaction mixture was cooled to 0 °C in an ice bath. DIAD (31.1 mL, 158.0 mmol, 2.2 equiv) was then added slowly to this mixture, and the resulting solution was stirred at 0 °C for 30 min and then overnight at room temperature. Solvents were removed by a rotary evaporator, and the residue was recrystallized from MeOH/DCM (1/1) by slow removal of the dichloromethane on the rotary evaporator. Crystals were filtered using a fine sintered-glass funnel and washed with cold methanol (–18 °C). The product was dried under reduced pressure to yield **2-Cl** as a yellow solid (24.1 g, 71%). ^1H NMR (CDCl_3 , 300 MHz): δ 9.22 (s, 1H), 7.57 (s, 2H), 4.16

(d, $^3J_{\text{HH}} = 6.4$ Hz, 4H), 4.11 (s, 6H), 2.37 (m, 2H), 1.21 (d, $^3J_{\text{HH}} = 6.8$ Hz, 12H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 166.2, 163.8, 152.0, 144.4, 134.6, 122.5, 115.1, 99.8, 75.7, 53.7, 28.4, 19.3. Mp: 261–263 °C. HRMS (ESI): m/z calcd for $\text{C}_{24}\text{H}_{27}\text{ClN}_2\text{O}_6$ [$\text{M} + \text{H}$] $^+$ 475.1636, found 475.1634. X-ray structure: see the Supporting Information.

Dimethyl 1,8-Diaza-4,5-diisobutoxy-9-amino-2,7-anthracenedicarboxylate (2-NH₂). In a dry 25 mL round-bottomed flask **1-Cl** (0.50 g, 1.1 mmol) and triphenylphosphine (0.55 g, 2.2 mmol, 2.0 equiv) were slurried in 8.5 mL of DMF. Sodium azide (0.14 g, 2.2 mmol, 2.0 equiv) was added, and the solution was heated to 120 °C. The reaction was then monitored by TLC (50/50 Hex/EtOAc). When the starting material was no longer visible, 1 N HCl (1.69 mL) was added and the reaction mixture was stirred for an additional 3 h. Solvent was removed by azeotropic distillation with toluene on a rotary evaporator. The crude orange-red solid was purified by recrystallization from DCM/MeOH to give **1-NH₂** as a bright red solid (0.30 g, 63%). ^1H NMR (CDCl_3 , 300 MHz): δ 8.19 (s, 1H), 7.44 (s, 2H), 6.68 (bs, 2H), 4.09 (d, $^3J_{\text{HH}} = 6.4$ Hz, 4H), 4.06 (s, 6H), 2.36 (m, 2H), 1.18 (d, $^3J_{\text{HH}} = 6.8$ Hz, 12H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 166.4, 163.0, 146.1, 145.1, 133.4, 122.7, 99.8, 98.3, 75.1, 53.1, 26.5, 19.4. Mp: 200–202 °C. HRMS (ESI): m/z calcd for $\text{C}_{24}\text{H}_{30}\text{N}_3\text{O}_6$ [$\text{M} + \text{H}$] $^+$ 456.2135, found 456.2134. X-ray structure: see the Supporting Information.

Dimethyl 1,8-Diaza-4,5-diisobutoxy-9-[bis(tert-butoxycarbonyl)amino]-2,7-anthracenedicarboxylate (2-NBoc₂). In a dry 25 mL round-bottomed flask **2-NH₂** (0.25 g, 0.5 mmol) was slurried in 4 mL of dioxane. Di-tert-butyl dicarbonate (1.20 g, 5.0 mmol, 10.0 equiv), diisopropylethylamine (0.28 mL, 5.0 mmol, 10.0 equiv), and dimethylaminopyridine (0.07 g, 0.5 mmol, 1.0 equiv) were added, and the solution was stirred overnight at 70 °C. Solvent was removed, and the crude yellow solid was purified by column chromatography with cyclohexane/EtOAc (50/50). Solvent was removed on a rotary evaporator, and the product was recrystallized from DCM/MeOH to give **2-Boc₂** as a light yellow solid (0.29 g, 81%). ^1H NMR (CDCl_3 , 300 MHz): δ 9.22 (s, 1H), 7.48 (s, 2H), 4.13 (d, $^3J_{\text{HH}} = 6.42$ Hz, 4H), 4.01 (s, 6H), 2.32 (m, 2H), 1.34 (s, 18H), 1.19 (d, $^3J_{\text{HH}} = 6.8$ Hz, 12H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 166.7, 163.3, 152.4, 151.3, 143.4, 135.8, 122.0, 116.0, 99.3, 82.1, 75.4, 52.9, 28.4, 28.0, 19.3. Mp: 207–212 °C. HRMS (ESI): m/z calcd for $\text{C}_{34}\text{H}_{46}\text{N}_3\text{O}_{10}$ [$\text{M} + \text{H}$] $^+$ 656.3183, found 656.3196.

Dimethyl 1,8-Diaza-4,5-diisobutoxy-9-[benzylmercapto]-2,7-anthracenedicarboxylate (2-SBn). In a dry 25 mL round-bottomed flask **2-Cl** (1.00 g, 2.1 mmol), and Cs_2CO_3 (0.89 g, 2.7 mmol, 1.3 equiv) were slurried in 5 mL of toluene. Benzyl mercaptan (0.32 mL, 2.7 mmol, 1.3 equiv) was added, and the solution was stirred at room temperature overnight. Solvent was removed on a rotary evaporator, and the crude orange-red solid was purified by column chromatography with toluene/EtOAc (80/20). Solvent was removed on the rotary evaporator, and the product was recrystallized from DCM/MeOH to give **2-SBn** as a bright red solid (1.02 g, 86%). ^1H NMR (CDCl_3 , 300 MHz): δ 9.08 (s, 1H), 7.53 (dd, $J_{\text{ortho}} = 6.5$, $J_{\text{meta}} = 1.5$ Hz, 2H), 7.49 (s, 2H), 7.23–7.16 (m, 3H), 5.22 (s, 2H), 4.12 (d, $^3J_{\text{HH}} = 6.2$, 4H), 4.07 (s, 6H), 2.35 (m, 2H), 1.19 (d, $^3J_{\text{HH}} = 6.8$ Hz, 12H). ^{13}C NMR (CDCl_3 , 75 MHz): δ 166.5, 163.7, 149.8, 147.0, 139.6, 136.8, 129.8, 128.3, 127.0, 122.1, 114.2, 99.2, 75.4, 53.3, 40.9, 28.5, 19.3. Mp: 217–219 °C. HRMS (ESI): m/z calcd for $\text{C}_{31}\text{H}_{35}\text{N}_2\text{O}_6\text{S}$ [$\text{M} + \text{H}$] $^+$ 563.2216, found 563.2221. X-ray structure: see the Supporting Information.

Dimethyl 1,8-Diaza-4,5-diisobutoxy-9,10-dihydro-2,7-anthracenedicarboxylate (2-H₂). In a dry 250 mL round-bottomed flask, **2-Cl** (10.0 g, 21.1 mmol), K_2CO_3 (20.4 g, 147.7 mmol, 7.0 equiv), and 10% Pd/C (2.2 g) were slurried in 100 mL of dry DMF. Nitrogen was then bubbled through the solution for 15 min to remove oxygen. The solution was then saturated with H_2 by passing a stream of H_2 through the solution for 15 min. The reaction mixture was then kept under an atmosphere of H_2 (provided by a balloon) for several hours (5–6 h was usually sufficient) while carefully being monitored by TLC (1% MeOH in DCM). When the starting material was no longer visible, the reaction mixture was diluted with DCM and passed through Celite. After removal of solvent on a rotary evaporator, the crude product was

triturated with MeOH and collected by filtration. After drying on the vacuum line **2-H₂** was obtained as an off-white solid (7.3 g, 79%). ¹H NMR (CDCl₃, 300 MHz): δ 7.56 (s, 2H), 4.50 (t, ³J_{HH} = 3.0 Hz, 2H), 4.05 (t, ³J_{HH} = 3.0 Hz, 2H), 4.01 (s, 6H), 3.94 (d, ³J_{HH} = 6.4 Hz, 4H), 2.21 (m, 2H), 1.11 (d, ³J_{HH} = 6.8 Hz, 12H). ¹³C NMR (CDCl₃, 75 MHz): δ 166.2, 163.1, 155.7, 147.9, 120.9, 106.3, 74.8, 53.1, 40.2, 28.3, 22.1, 19.1. Mp: 213–216 °C. HRMS (ESI): *m/z* calcd for C₂₄H₃₁N₂O₆ [M + H - H₂]⁺ 441.2026, found 441.2024. The loss of hydrogen from protonated 9,10-dihydroanthracenes, to give the [M - H]⁺ cation, is an established phenomenon in 9,10-dihydroanthracenes.⁴¹ X-ray structure: see the Supporting Information.

Dimethyl 1,8-Diaza-4,5-diisobutoxy-2,7-anthracenedicarboxylate (2). **2-H₂** (5.0 g, 11.3 mmol) and dry carbon (2.5 g) were slurried in 50 mL of dry toluene in a 250 mL round-bottomed flask. The solution was placed under an O₂ atmosphere and heated to 100 °C for 16 h. The reaction mixture was then diluted with 200 mL of DCM and poured onto a pad of silica. The product was then eluted with 2% MeOH in DCM. Solvent was removed on a rotary evaporator, and the product was recrystallized from DCM/MeOH to give **2** as a bright yellow solid (4.2 g, 84%). ¹H NMR (CDCl₃, 300 MHz): δ 9.27 (s, 1H), 9.18 (s, 1H), 7.51 (s, 2H), 4.15 (d, ³J_{HH} = 6.4 Hz, 4H), 4.11 (s, 6H), 2.37 (m, 2H), 1.20 (d, ³J_{HH} = 6.8 Hz, 12H). ¹³C NMR (CDCl₃, 75 MHz): δ 166.2, 163.3, 151.6, 147.7, 131.0, 122.0, 116.9, 99.1, 75.3, 53.5, 28.3, 19.2. Mp: 244–246 °C. HRMS (ESI): *m/z* calcd for C₂₄H₂₉N₂O₆ [M + H]⁺ 441.2026, found 441.2022. X-ray structure: see the Supporting Information.

Dimethyl 1,8-Diaza-4,5-diisobutoxy-9-bromo-2,7-anthracenedicarboxylate (2-Br). In a dry 25 mL round-bottomed flask, compound **2** (0.50 g, 1.1 mmol) and freshly recrystallized NBS (0.24 g, 1.3 mmol, 1.2 equiv) were slurried in 10 mL of a 1/1 mixture of CHCl₃ and DMF. The solution was heated to 60 °C and stirred overnight. Solvent was then removed, and the crude product was purified by column chromatography using 10% EtOAc/90% toluene to obtain **2-Br** (0.41 g, 70%). ¹H NMR (CDCl₃, 300 MHz): δ 9.29 (s, 1H), 7.57 (s, 2H), 4.17 (d, ³J_{HH} = 6.2 Hz, 2H), 4.11 (s, 6H), 2.37 (m, 2H), 1.21 (d, ³J_{HH} = 6.6 Hz, 12H). ¹³C NMR (CDCl₃, 75 MHz): δ 166.2, 163.9, 152.3, 145.7, 122.9, 116.3, 99.7, 75.7, 53.7, 28.5, 27.1, 19.3. Mp: 253–259 °C. HRMS (ESI): *m/z* calcd for C₂₄H₂₈BrN₂O₆ [M + H]⁺ 519.1131, found 519.1132. X-ray structure: see the Supporting Information.

1,8-Diaza-4,5-diisobutoxy-7-(methoxycarbonyl)-2-anthracenecarboxylic Acid (3). **2** (4.00 g, 9.1 mmol) was slurried in boiling MeOH (200 mL) and heated to 65 °C with stirring until all of the solid dissolved. To this solution was added dropwise KOH (0.76 g, 13.6 mmol, 1.5 equiv) dissolved in 20 mL of MeOH. The reaction mixture was stirred at 65 °C until a precipitate was observed. The reaction mixture was then cooled to 35 °C and stirred overnight. The solid was collected by filtration and washed with cold MeOH, 5% citric acid solution, and then water. After it was dried on the filter for 1 h, the solid was redissolved in DCM and further dried over Na₂SO₄. The solution was then filtered and solvent removed on a rotary evaporator. After drying on the vacuum line, **3** was obtained as a yellow solid (3.50 g, 90%). ¹H NMR (CDCl₃, 300 MHz): δ 9.31 (s, 1H), 9.04 (s, 1H), 7.58 (s, 1H), 7.55 (s, 1H), 4.19 (d, ³J_{HH} = 6.4 Hz, 2H), 4.17 (d, ³J_{HH} = 6.4 Hz, 2H), 4.13 (s, 3H), 2.39 (m, 2H), 1.21 (d, ³J_{HH} = 6.8 Hz, 6H), 1.20 (d, ³J_{HH} = 6.8 Hz, 6H). ¹³C NMR (CDCl₃, 75 MHz): δ 166.1, 165.0, 164.3, 163.6, 152.2, 150.3, 147.9, 145.5, 129.3, 122.4, 122.1, 117.8, 99.6, 97.2, 76.0, 75.6, 53.7, 28.4, 28.4, 19.3, 19.3. HRMS (ESI): *m/z* calcd for C₂₃H₂₇N₂O₆ [M + H]⁺ 427.1864, found 427.1861.

Sodium 1,8-Diaza-4,5-diisobutoxy-7-(methoxycarbonyl)-9-methyl-2-anthracenecarboxylate (3-Me). Compound **1** (10.0 g, 22.0 mmol) was placed in a 1 L round-bottomed flask and dissolved in 750 mL of THF/MeOH (75/25 v/v). NaOH (1.01 g, 25.3 mmol, 1.15 equiv) dissolved in MeOH (20 mL) was slowly added to this mixture. The reaction mixture was then stirred at room temperature for 24 h, during which time the product precipitated from solution. The white/yellow solid was collected by filtration and washed with cold MeOH. The solid was dried under vacuum to give the sodium salt of the monocarboxylate of **1** (**3-Me**) as a light yellow solid (9.1 g, 89%). The compound was used in this form for subsequent reactions. However, because of the limited solubility of **3-Me** in the carboxylate form, for

characterization, 100 mg of **3-Me** was washed with a 5% citric acid solution and then extracted into CHCl₃. After it was washed with water and brine, the solution was dried over Na₂SO₄. Solvent was removed on a rotary evaporator and the residue then dried under vacuum to give the carboxylic acid. ¹H NMR (CDCl₃, 300 MHz): δ 9.19 (s, 1H), 7.58 (s, 1H), 7.52 (s, 1H), 4.18 (d, ³J_{HH} = 6.4 Hz, 2H), 4.15 (d, ³J_{HH} = 6.4 Hz, 2H), 4.11 (s, 3H), 3.43 (s, 3H), 2.38 (m, 2H), 1.21 (d, ³J_{HH} = 6.8 Hz, 6H), 1.20 (d, ³J_{HH} = 6.8 Hz, 6H). ¹³C NMR (CDCl₃, 75 MHz): δ 166.2, 164.9, 164.3, 163.3, 150.3, 147.9, 145.7, 143.3, 137.1, 121.6, 121.1, 114.0, 99.2, 96.4, 75.7, 75.3, 53.3, 28.5, 28.4, 19.3, 19.2, 12.7. HRMS (ESI): *m/z* calcd for C₂₄H₂₉N₂O₆ [M + H]⁺ 441.2020, found 441.2018.

Methyl 1,8-Diaza-4,5-diisobutoxy-7-[(tert-butoxycarbonyl)amino]-2-anthracenecarboxylate (4). In a dry 100 mL round-bottomed flask equipped with a stir bar, **3** (3.46 g, 8.1 mmol) was slurried in 25 mL of dry toluene under a nitrogen atmosphere. DIPEA (2.83 mL, 16.2 mmol, 2 equiv) and DPPA (3.49 mL, 16.2 mmol, 2 equiv) were added, and the reaction mixture was stirred at room temperature overnight. The reaction mixture was then diluted with an additional 20 mL of dry toluene, and anhydrous *t*BuOH (40 mL) was added. The flask was then transferred to a 100 °C oil bath and the mixture stirred for 6 h. Solvent was removed on a rotary evaporator, and the crude material was redissolved in 1/1 DCM/MeOH. After slow evaporation of DCM on the rotary evaporator, the solid product was collected by filtration and dried under vacuum to yield **4** as a light yellow solid (2.49 g, 62%). ¹H NMR (CDCl₃, 300 MHz): δ 9.11 (s, 1H), 8.60 (s, 1H), 7.68 (s, 1H), 7.66 (s, 1H), 7.44 (s, 1H), 4.12 (d, ³J_{HH} = 6.4 Hz, 2H), 4.11 (d, ³J_{HH} = 6.4 Hz, 2H), 4.10 (s, 3H), 2.35 (m, 2H), 1.55 (s, 9H), 1.19 (d, ³J_{HH} = 6.8 Hz, 6H), 1.18 (d, ³J_{HH} = 6.8 Hz, 6H). ¹³C NMR (CDCl₃, 75 MHz): δ 166.6, 163.6, 163.4, 154.7, 152.7, 151.0, 148.2, 147.4, 126.1, 120.8, 119.4, 116.8, 98.3, 92.4, 81.6, 75.2, 75.0, 53.5, 28.4, 19.4, 19.3. Mp: 258–263 °C. HRMS (ESI): *m/z* calcd for C₂₇H₃₆N₃O₆ [M + H]⁺ 498.2604, found 498.2605.

Methyl 1,8-Diaza-4,5-diisobutoxy-7-[(tert-butoxycarbonyl)amino]-9-methyl-2-anthracenecarboxylate (4-Me). The sodium salt of **3-Me** (10.0 g, 21.7 mmol), in a nitrogen-flushed 250 mL round-bottomed flask equipped with a septum and stir bar, was slurried in dry DCM (50 mL). A needle was inserted into the septum to act as a gas vent while oxalyl chloride (12.9 mL, 151.6 mmol, 7 equiv) was added slowly to the mixture via a syringe. The reaction mixture was stirred for 2–4 h at room temperature, after which time the solution turned orange and appeared slightly cloudy. Solvent was removed under vacuum, and the yellow-orange solid was further dried on a vacuum line for 4 h. The solid was then redissolved in dry DCM (50 mL), and trimethylsilyl azide (8.5 mL, 65.0 mmol, 3 equiv) was added. The mixture was then stirred overnight (12 h) at room temperature. Solvent was removed under vacuum. Anhydrous *t*BuOH (50 mL) was then added via syringe and the resulting yellow slurry refluxed for 12 h. Solvent was removed with a rotary evaporator. The crude solid was then dissolved in DCM and filtered through Celite. After removal of solvent, the mixture was recrystallized by slow evaporation of DCM from a 2/1 mixture of DCM and MeOH to give **4-Me** as a bright yellow solid (8.5 g, 77%). ¹H NMR (CDCl₃, 300 MHz): δ 9.01 (s, 1H), 7.67 (s, 1H), 7.56 (s, 1H), 7.42 (s, 1H), 4.11 (d, ³J_{HH} = 6.4 Hz, 4H), 4.08 (s, 3H), 3.23 (m, 3H), 2.34 (m, 2H), 1.57 (s, 9H), 1.19 (d, ³J_{HH} = 6.8 Hz, 6H), 1.18 (d, ³J_{HH} = 6.4 Hz, 6H). ¹³C NMR (CDCl₃, 75 MHz): δ 166.7, 163.6, 163.5, 152.9, 152.6, 149.3, 146.2, 145.2, 133.6, 119.9, 119.0, 113.4, 97.7, 91.9, 81.3, 74.9, 53.2, 28.4, 19.3, 12.6. Mp: 233–235 °C. HRMS (ESI): *m/z* calcd for C₂₈H₃₈N₃O₆ [M + H]⁺ 512.2761, found 512.2760.

■ ASSOCIATED CONTENT

☉ Supporting Information

Figures giving NMR spectra for all compounds and figures, tables, and CIF files giving crystallographic data for **1-Br**, **1-ONO₂**, **1-OAc**, **1-N₃**, **2-Cl**, **2-H₂**, **2**, **2-NH₂**, **2-SBn**, and **2-Br** and the byproducts **2-Cl^{red}** and **4-dimer**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail for I.H.: i.huc@iecb.u-bordeaux.fr.

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was supported by the European Union's Seventh Framework Programme through Marie Curie actions (PIIF-GA-2010-275209 postdoctoral fellowship to M.L.S.) and through the European Research Council (Grant Agreements No. ERC-2012-AdG-320892), by COST action CM0803 (travel grant to N.C.) and by the Fondation Simone et Cino Del Duca de l'Institut de France (Post-Doctoral Fellowship to M.L.S.).

■ REFERENCES

- (1) Goodman, C. M.; Choi, S.; Shandler, S.; DeGrado, W. F. *Nat. Chem. Biol.* **2007**, *3*, 252.
- (2) Guichard, G.; Huc, I. *Chem. Commun.* **2011**, *47*, 5933.
- (3) Montalvo, G.; Waegle, M. M.; Shandler, S.; Gai, F.; DeGrado, W. F. *J. Am. Chem. Soc.* **2010**, *132*, 5616.
- (4) Dohm, M. T.; Mowery, B. P.; Czyzewski, A. M.; Stahl, S. S.; Gellman, S. H.; Barron, A. E. *J. Am. Chem. Soc.* **2010**, *132*, 7957.
- (5) Zhao, Y.; Zhong, Z. *J. Am. Chem. Soc.* **2006**, *127*, 17894.
- (6) Odriozola, I.; Kyritsakas, N.; Lehn, J.-M. *Chem. Commun.* **2004**, *62*.
- (7) Jamieson, A. G.; Russell, D.; Hamilton, A. D. *Chem. Commun.* **2012**, *48*, 3709.
- (8) Cheng, P.-N.; Spencer, R.; Woods, J. R.; Glabe, C. G.; Nowick, J. S. *J. Am. Chem. Soc.* **2012**, *134*, 14179.
- (9) Appella, D. H.; Christianson, L. A.; Karle, I. L.; Powell, D. R.; Gellman, S. H. *J. Am. Chem. Soc.* **1996**, *118*, 13071.
- (10) Cheng, R. P.; Gellman, S. H.; DeGrado, W. F. *Chem. Rev.* **2001**, *101*, 3219.
- (11) Seebach, D.; Beck, A. K.; Bierbaum, D. J. *Chem. Biodivers.* **2004**, *1*, 1111.
- (12) Li, X.; Wu, Y. D.; Yang, D. *Acc. Chem. Res.* **2008**, *41*, 1428.
- (13) Stone, M. T.; Heemstra, J. M.; Moore, J. S. *Acc. Chem. Res.* **2006**, *39*, 11.
- (14) Leung, S. Y.-L.; Tam, A. Y.-Y.; Tao, C.-H.; Chow, H. S.; Yam, V. W.-W. *J. Am. Chem. Soc.* **2012**, *134*, 1047.
- (15) Azeroual, S.; Surprenant, J.; Lazzara, T. D.; Kocun, M.; Tao, Y.; Cuccia, L. A.; Lehn, J.-M. *Chem. Commun.* **2012**, *48*, 2292.
- (16) Cuccia, L. A.; Ruiz, E.; Lehn, J.-M.; Homo, J. C.; Schmutz, M. *Chem. Eur. J.* **2002**, *8*, 3448.
- (17) Fremaux, J.; Fischer, L.; Arbogast, T.; Kauffmann, B.; Guichard, G. *Angew. Chem., Int. Ed.* **2011**, *50*, 11382.
- (18) Mousseau, J. J.; Xing, L.; Tang, N.; Cuccia, L. A. *Chem. Eur. J.* **2009**, *15*, 10030.
- (19) Zhang, D.-W.; Zhao, X.; Hou, J.-L.; Li, Z.-T. *Chem. Rev.* **2012**, *112*, 5271.
- (20) Huc, I. *Eur. J. Org. Chem.* **2004**, *17*.
- (21) Yamato, K.; Kline, M.; Gong, B. *Chem. Commun.* **2012**, *48*, 12142.
- (22) Juwarker, H.; Suk, J.-m.; Jeong, K.-S. *Chem. Soc. Rev.* **2009**, *38*, 3316.
- (23) Ferrand, Y.; Kendhale, A. M.; Kauffmann, B.; Grélard, A.; Marie, C.; Blot, V.; Pipelier, M.; Dubreuil, D.; Huc, I. *J. Am. Chem. Soc.* **2010**, *132*, 7858.
- (24) Bao, C.; Gan, Q.; Kauffmann, B.; Jiang, H.; Huc, I. *Chem. Eur. J.* **2009**, *15*, 11530.
- (25) Bao, C.; Kauffmann, B.; Gan, Q.; Srinivas, K.; Jiang, H.; Huc, I. *Angew. Chem., Int. Ed.* **2008**, *47*, 4153.
- (26) Berni, E.; Garric, J.; Lamit, C.; Kauffmann, B.; Léger, J.-M.; Huc, I. *Chem. Commun.* **2008**, 1968.
- (27) Hall, C. M.; Wright, J. B.; Johnson, H. G.; Taylor, A. J. *J. Med. Chem.* **1977**, *20*, 1337.
- (28) Cheney, B. V.; Christoffersen, R. E. *J. Med. Chem.* **1983**, *26*, 726.
- (29) Jain, R.; Caldwell, S. L.; Louie, A. S.; Hicks, R. G. *Can. J. Chem.* **2006**, *84*, 1263.
- (30) Zhang, J.; Karabunarliev, S.; Baumgarten, M. *Chem. Phys.* **1996**, *339*.
- (31) Gan, Q.; Shang, J.; Kauffmann, B.; Wang, Y.; Bie, F.; Jiang, H. *Tetrahedron Lett.* **2012**, *68*, 4479.
- (32) Gan, Q.; Ferrand, Y.; Bao, C.; Kauffmann, B.; Grélard, A.; Jiang, H.; Huc, I. *Science* **2011**, *331*, 1172.
- (33) Berni, E.; Dolain, C.; Kauffmann, B.; Leger, J.-M.; Zhan, C.; Huc, I. *J. Org. Chem.* **2008**, *73*, 2687.
- (34) Berni, E.; Kauffmann, B.; Bao, C.; Lefevre, J.; Bassani, D. M.; Huc, I. *Chem. Eur. J.* **2007**, *13*, 8463.
- (35) Zewge, D.; Chen, C.-y.; Deer, C.; Dormer, P. G.; Hughes, D. L. *J. Org. Chem.* **2007**, *72*, 4276.
- (36) On the basis of the results reported herein, the 9-hydro derivative reported by Zhu et al. is rather an impurity that has been mistaken for their desired product: Zhu, H.; Guan, Z.; Zhan, C. *Youji Huaxue* **2010**, *30*, 1716.
- (37) Grehn, L.; Ragnarsson, U. *Synthesis* **1987**, *3*, 275.
- (38) Kandalkar, S. R.; Kaduskar, R. D.; Ramaiah, P. A.; Barawkar, D. A.; Bhuniya, D.; Deshpande, A. M. *Tetrahedron Lett.* **2013**, *54*, 414.
- (39) Hayashi, M. *Chem. Rec.* **2008**, *8*, 252.
- (40) Zhou, J.; Matos, M.-C.; Murphy, P. V. *Org. Lett.* **2011**, *13*, 5716.
- (41) Vala, M.; Szczepanski, J.; Oomens, J. *Int. J. Mass. Spectrom.* **2011**, *308*, 181.